Trial finds risk, but no benefit, with blood thinner ...

To receive coverage for Xarelto, a person must be enrolled in a Medicare Part D prescription drug plan or a Medicare Advantage (Part C) plan that includes prescription drug coverage. This article ...

Raritan, NJ (July 1, 2011) - Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban tablets), a novel, once-daily, oral ...

Rivaroxaban(Xarelto, Janssen) received FDA approval today for the prevention of deep vein thrombosis which may lead to a pulmonary embolism in patients undergoing knee or hip replacement surgery. The ...

PIONEER AF-PCI exploratory trial found that elderly patients experienced a lower rate of clinically significant bleeding after 12 months of treatment with Xarelto (rivaroxaban). Johnson & Johnson has ...

RARITAN, N.J., June 23, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug ...

Providing validation to what many physicians are already doing, a new study suggests that non-vitamin K antagonist oral anticoagulants (NOACs)—rivaroxaban, in particular—are effective alternatives to ...

XARELTO® is the only new oral anticoagulant with FDA approval in this indication Raritan, NJ (July 1, 2011) /PRNewswire/ - Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug ...

RARITAN, N.J., July 1, 2011 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban tablets), a novel, ...